The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Covidien's revenues will compress -3.2% and EPS will decrease -7.4%.
The average estimate for revenue is $2.98 billion. On the bottom line, the average EPS estimate is $1.00.
Last quarter, Covidien reported revenue of $3.01 billion. GAAP reported sales were 2.8% higher than the prior-year quarter's $2.93 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.07. GAAP EPS of $0.93 for Q3 were 13% lower than the prior-year quarter's $1.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 58.0%, 90 basis points better than the prior-year quarter. Operating margin was 22.1%, about the same as the prior-year quarter. Net margin was 15.1%, 320 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $11.84 billion. The average EPS estimate is $4.25.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Covidien is buy, with an average price target of $63.22.
- Add Covidien to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien Ltd. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.